Tarsus Pharmaceuticals Announces Appointment of New COO and CFO
Sesha Neervannan, PhD, to assume position of Chief Operating Officer; Leo Greenstein to assume position of Chief Financial Officer
Optometric Management Interviews TearClear CEO Robert Dempsey
Robert J. Dempsey recently joined TearClear, an emerging global ophthalmic pharmaceutical company with a focus on eye drops that are preserved safely prior to administering dosing, as Chief Executive Officer. Prior to this role, Mr. Dempsey held positions at Shire (Takeda, now Novartis), Bausch + Lomb, Allergan and Inspire Pharmaceuticals. What follows is a Q&A with Mr. Dempsey, where he reveals, among other things, his love of American history.
Re-Vana Therapeutics Completes of $3.25MM Pre-Series A Financing
Re-Vana Completes $3.25MM Pre-Series A Financing led by Visionary Ventures and ExSight Ventures to Support Pre-clinical Development of Sustained Release Biologic and Small Molecule Therapeutics.
Tarsus Presents Positive Phase IIb Results of TP-03
Tarsus Presents Positive Results of the Jupiter Study, a Phase 2b Randomized Controlled Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Blepharitis Due to Demodex Infestation, at AOA 2020 Virtual Meeting
Elad Kedar and Jeffry Weinhuff, the CEO and Chairman of Orasis Interviewed on OIS Podcast
Elad Kedar, CEO of Orasis Pharmaceuticals shares his strategy for successfully completing a Phase 2b clinical study in preparation of their phase 3 of CSF-1 drops for temporary correction of presbyopia. Jeffry Weinhuff from Visionary Ventures joins the conversation as Chairman of the Board to explain how he evaluated the Orasis technology and what VCs look for.
Ophthalmology Investing in Orange County in Orange County Business Journal Article
Orange County Business Journal (OCBJ) interviews Visionary Ventures managing partner Jeffry Weinhuff and a Flying L managing partner Bill Link about investing in ophthalmology.
Robert Dempsey the New CEO of TearClear Interviewed on OIS Podcast
In this week’s OIS Podcast, Dr. Ehsan Sadri speaks with Bob Dempsey who just assumed the CEO role for TearClear. Let’s hear how Bob’s experience taking Xiidra to market for Shire led him to the driver’s seat for one of the most promising new drug-delivery companies.
TearClear Completes Initial Close of $25MM Series B Financing
TearClear Completes Initial Close of $25MM Series B Financing led by Visionary Ventures, Bluestem Capital, and Flying L. Additionally, TearClear has appointed Robert Dempsey to the CEO role. Robert Dempsey and Bill Link were interviewed by Eyewire news about the latest financing and CEO appointment.
Jeffry Weinhuff, Visionary Managing Partner, Interviewed about Life Science Investing for the Long Haul
Q&A with Jeffry Weinhuff from Visionary Ventures on how life science investors view the current COVID-19 climate, what opportunities might arise, and what health care innovations are more important now more than ever.
Tarsus Pharmaceuticals Completes $60MM Series B Financing
Tarsus Pharmaceuticals completes $60MM Series B financing